Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Demand for private health cover surge amid NHS waiting list crisis

Demand for private health cover surge amid NHS waiting list crisis

The UK health cover market was valued at £6.7 billion in 2022, marking a £385 million increase from the previous year

Challenges in accessing the NHS waiting list are pushing more and more people toward private-funded alternatives for access, diagnosis and treatment, thereby increasing the demand for private health cover.

According to a report published by health data provider LaingBuisson, the demand for private health cover, including medical and dental insurance and cash plans, has surged to its highest levels since 2008.


The UK’s overall health cover market reached £6.7 billion in 2022, an increase of £385 million from the previous year.

During the period from 2020 to 2022, the market experienced annual growth rate of 6.1 per cent, a significant increase compared to the average annual growth rate of 1.7 per cent observed between 2008 and 2019, the research found.

A total of 4.2 million people were subscribed to medical cover schemes in 2022. When dependents covered by these policies were included, the number reached 7.3 million – the highest count since 2008.

LaingBuisson’s analysis showed that medical cover volumes were steady through most of the 2010s, but began to increase alongside rises in the NHS waiting list from 2018.

Nevertheless, high inflation resulted in the market's real-terms value declining by 2.2 per cent despite its growth.

Tim Read, author of the report, said: “Despite a real-terms fall in overall market value, the broader picture for the health cover market is positive. Uplifts in subscriber volumes following the pandemic should translate to overall growth in market value as background inflation declines.”

Did Covid lead to the surge?

Read said: “The pandemic may have driven increased demand, but it is misleading to suggest it is the cause of it.

“LaingBuisson’s analysis shows a longer, deeper relationship between the length of the NHS waiting list and demand for health insurance. Demand began to increase in 2018, as the NHS waiting list began to rise out of control.”

Drawing from their study findings, Read maintained that “without substantial inroads into making NHS-funded care accessible within acceptable timescales for patients, health cover products will continue to grow in demand.”

LaingBuisson’s study revealed that the growth in the UK health cover market is primarily driven by company-backed schemes.

Read said that this might be because of “an increased awareness of the impact of employee ill-health on a business – and possibly frustration at the impact that an inaccessible NHS is having on productivity.”

“Investing in a product that enables people to see primary or secondary care specialists when they need to, rather than having a take a day off work hoping for an appointment, is no longer necessarily seen as a perk but as something critical to ongoing business success,” he added.

Private medical cover – which includes Private Medical Insurance (PMI) and company-paid self-insurance schemes, accounted for 80 per cent of the total market value at £5.3 billion in 2022 -  a six per cent increase from 2021 and a 9.6 per cent increase since the last full year before the pandemic in 2019.

Health cash plans were valued at £461m in 2022, dental capitation subscriptions at £688 million, and dental insurance at £180 million.

More For You

A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less
Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Patients to get test results via NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

Keep ReadingShow less
Health minister assures House of Lords on measures to tackle UK-wide Creon drug shortage

Baroness Merron

Government taking steps to mitigate shortage of cancer drug Creon

Baroness Merron on Monday (9) assured the House of Lords that the government is taking measures to mitigate the shortage of pancreatic cancer drug Creon across the country.

Raising the issue, Baroness Margaret Ritchie wanted to know about the steps being taken by the government to ease the misery of patients suffering from pancreatic cancer.

Keep ReadingShow less
Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Janet Morrison

Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Community Pharmacy England (CPE) chief executive Janet Morrison has welcomed chancellor Rachel Reeves announcement today that day-to-day spending on the NHS will increase by £29bn a year but insisted that it must reflect in securing the future of pharmacy.

Reeves also revealed that the government will be increasing the NHS technology budget by almost 50 per cent, with £10bn of investment to "bring our analogue health system into the digital age, including through the NHS app".

Keep ReadingShow less
Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less